Tislelizumab, Carboplatin, Pemetrexed

DRUG2 trials

Sponsors

Sun Yat-sen University, Second Affiliated Hospital of Nanchang University

Conditions

Brain MetastasesNSCLC Stage IVNon-Small Cell Lung CancerPD-1 Antibody

Phase 2

Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC

CompletedNCT04507217

Sun Yat-sen UniversityBrain Metastases, NSCLC Stage IV, PD-1 Antibody

Start: 2020-09-15End: 2023-01-30Updated: 2023-05-25

SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC

RecruitingNCT07131319

Second Affiliated Hospital of Nanchang UniversityNon-Small Cell Lung Cancer

Start: 2025-04-21End: 2028-12-31Target: 30Updated: 2026-06-25

Related Papers

Tislelizumab plus chemotherapy in patients with advanced brain metastases of non-squamous non-small cell lung cancer: A multicenter, prospective, open-label phase 2 study.

Journal of Clinical Oncology2023-06-012 citations